As populations age worldwide, the decline of the immune system, a process known as immunosenescence, has become a critical biomedical challenge. This decline leads to increased susceptibility to ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

Engineered HLA-independent T cell receptors have eliminated kidney, ovarian and pancreatic tumours in laboratory studies by detecting minute levels of CD70 which may open a route to broader solid ...

Researchers engineer CAR-astrocytes to target and remove amyloid plaques in Alzheimer’s, showing a 50% reduction in brain ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of ...

A conserved glucagon signaling pathway links high-fat diet-induced metabolic imbalance to cardiac arrhythmia through hormone-producing cells and heart-innervating neurons that regulate rhythmicity.

CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

A single treatment of viral vector-delivered CAR-A construct in mice with existing plaque saturation cut the amount of amyloid plaques in half.